基于VOSviewer的PARP抑制剂文献计量学分析  

Bibliometric Analysis of PARP Inhibitors Based on VOSviewer

作　　者：莫嘉瑶 蒋炜 何志超[2] 黄民[1] 余晓霞[2] 伍俊妍[2] MO Jiayao;JIANG Wei;HE Zhichao;HUANG Min;YU Xiaoxia;WU Junyan(School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou,Guangdong 511400,China;Department of Pharmacy,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou,Guangdong 510030,China)

机构地区：[1]中山大学药学院,广东广州511400 [2]中山大学孙逸仙纪念医院药学部,广东广州510030

出　　处：《今日药学》2023年第4期290-294,共5页Pharmacy Today

摘　　要：目的了解近10年来PARP(poly ADP ribose polymerase)抑制剂的研究现状与发展趋势,为后续的相关研究提供参考。方法于Web of Science数据库检索2012~2021年PARP抑制剂相关文献,结合VOSviewer软件对相关文献的特征和被引情况进行可视化分析。结果本研究共检索到相关文献8403篇。近10年来,PARP抑制剂相关文献的发文量和被引频次呈逐年上升趋势。发文量位居全球第一的国家和机构分别是美国和得克萨斯大学,英国与伦敦大学在研究影响力方面表现突出;在该领域内最高产的作者为Kim Sung-hoon。文献的关键词共现分析显示,PARP抑制剂的研究热点从基础药理逐渐发展到适应证、治疗方案等临床应用方向,近期研究主要集中于临床试验。结论近年来,对PARP抑制剂的相关研究不断深入,美、英等国研究水平较为成熟。临床试验可能是未来的研究主题,为优化临床应用等提供证据。OBJECTIVE To understand the research progress and development trend of poly ADP ribose polymerase(PARP)inhibitors in the past 10 years to provide reference for further studies.METHODS Literature on PARP inhibitors from 2012 to 2021 were searched in Web of Science.Characteristics and citations of related literature were analyzed and visualized using the VOSviewer software.RESULTS 8403 eligible references were identified in this study.In the past 10 years,the number of related publications and citation frequencies had been continuously increasing.The country and institution having the largest publications of PARP inhibitors were the United States(U.S.)and University of Texas System,respectively.The United Kingdom(U.K.)and University of London also had high influence on the field of study.The most prolific author in the field was Kim Sung⁃hoon.The co⁃occurrence analysis of keywords showed that the research hotspot of PARP inhibitors had gradually developed,from pharmacology to clinical use including indications and regimens.Currently,related research had focused on clinical trials.CONCLUSION PARP⁃inhibitor⁃related studies have progressed in depth in recent years,with an advanced level of research in the U.S.and U.K.Clinical trials may be the mainstream of future studies,which will provide evidence for optimal clinical applications.

关 键 词：PARP抑制剂 文献计量学 可视化分析 VOSviewer 

分 类 号：R979[医药卫生—药品]